<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404479</url>
  </required_header>
  <id_info>
    <org_study_id>DIA IIT_01</org_study_id>
    <nct_id>NCT03404479</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA</brief_title>
  <acronym>DIA IIT_01</acronym>
  <official_title>A Prospective, Randomized, Double-blinded, Multi-center, Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered Orally in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Whan-Seok Choi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pain relief effect of Co-administration of&#xD;
      Diacerein with Celecoxib in patients with knee osteoarthritis compared with single&#xD;
      administration of each drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large epidemiological study in Europe reported that over four-thirds of patients with&#xD;
      osteoarthritis received combination therapy with two or more drugs. Approximately 1.5% of&#xD;
      patients with osteoarthritis using three or more drugs are using COX-2(Cyclo-oxygenase-2)&#xD;
      inhibitors and SYSADOA(Symptomatic slow acting drug), And it has been investigated that much&#xD;
      more patients are using the two classes of drugs when the range is extended to other oral&#xD;
      NSAIDs other than COX-2 inhibitors. Therefore, considering the characteristics of patients&#xD;
      with osteoarthritis, such as basal disease and treatment effects on each type of drug, it is&#xD;
      important to find the optimal combination of drugs for each patient characteristics.&#xD;
&#xD;
      There is a previous study using osteoarthritis rat model as a biological basis of diacerein&#xD;
      and celecoxib administration. Previous studies have shown that the combined use of Diacerein&#xD;
      and Celecoxib improves osteoarthritis.&#xD;
&#xD;
      The purpose of this study is to evaluate the pain relief effect of Co-administration of&#xD;
      Diacerein with Celecoxib in patients with knee osteoarthritis compared with single&#xD;
      administration of each drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">January 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain VAS score</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Changes in pain VAS(Visual analogue scale) score before and after 12 weeks of drugs administration.&#xD;
(No pain score: 0, Worst pain score: 100)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain NRS score</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Changes in pain NRS(Numeric rating scale) score before and after 12 weeks of drugs administration.&#xD;
(No pain score: 0, Worst pain score: 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC index score</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Changes in WOMAC(Western Ontario and mcmaster Universities Osteoarthritis Index) index score before and after 12 weeks of drugs administration (possible score range, Pain: 0-20, Stiffness: 0-8, Physical function: 0-68; Total Score range: 0-96 ('none' to 'extreme'))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSRS index score</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Changes in GSRS(Gastrointestinal symptom rating scale) index score before and after 12 weeks of drugs administration.&#xD;
(Score range: 0-45 ('none' to 'extreme'))</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Co-administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of Diacerein 50mg, Celecoxib 100mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single administration group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration of Diacerein 50mg and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single administration group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration of Celecoxib 100mg and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diacerein</intervention_name>
    <description>For 12 weeks, administered twice a day by oral.</description>
    <arm_group_label>Co-administration group</arm_group_label>
    <arm_group_label>Single administration group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>For 12 weeks, administered twice a day by oral.</description>
    <arm_group_label>Co-administration group</arm_group_label>
    <arm_group_label>Single administration group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who voluntarily consented, after listening enough explanation for this study&#xD;
             and investigational product.&#xD;
&#xD;
          2. Adult over 50 years of age.&#xD;
&#xD;
          3. At least one of the knee pain VAS score is 40mm or more.&#xD;
&#xD;
          4. Meets the ACR(American College of Rheumatology) criteria for diagnosis. (1)&#xD;
             Confirmation of osteophytes on radiographic inspection. (2) One or more of the&#xD;
             following three items.&#xD;
&#xD;
             ① Age&gt; 50 years&#xD;
&#xD;
             ② Morning stiffness &lt;30 minutes&#xD;
&#xD;
             ③ Crepitus&#xD;
&#xD;
          5. Patients who require medication for more than 12 weeks due to osteoarthritis symptoms.&#xD;
&#xD;
          6. Those who are able to follow the requirements of this clinical trial, such as being&#xD;
             able to trace during the clinical trial period and to read and write the VAS&#xD;
             questionnaire.&#xD;
&#xD;
          7. Those who weigh more than 40kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary knee osteoarthritis&#xD;
&#xD;
          2. Other inflammatory Knee Osteoarthritis (e.g. gout, rheumatoid arthritis, etc.)&#xD;
&#xD;
          3. Patients presenting with gastroesophageal reflux disease, peptic ulcer.&#xD;
&#xD;
          4. Helicobacter infected patients who have not been treated for eradication (recruitment&#xD;
             if negative in re-examination after treatment).&#xD;
&#xD;
          5. Short bowel syndrome that can cause inflammatory bowel disease (ulcerative colitis,&#xD;
             Crohn's disease) and drug absorption disorder.&#xD;
&#xD;
          6. Intestinal obstruction syndrome&#xD;
&#xD;
          7. Unexplained abdominal pain&#xD;
&#xD;
          8. ALT(Alanine aminotransferase) level of liver function test exceeded 5 times of&#xD;
             reference range&#xD;
&#xD;
          9. Total bilirubin level exceeded 2 mg / dL&#xD;
&#xD;
         10. Serum albumin level less than 2 g / dL&#xD;
&#xD;
         11. Ascites&#xD;
&#xD;
         12. Hepatic encephalopathy&#xD;
&#xD;
         13. Hepatitis B, hepatitis C (excluding healthy carriers) or HIV positive&#xD;
&#xD;
         14. MDRD(Modification of Diet in Renal Disease) Estimated Glomerular filtration rate less&#xD;
             than 60 mL / m2&#xD;
&#xD;
         15. Patients with hyperkalemia (over 5.5 meq / L)&#xD;
&#xD;
         16. history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or allergic&#xD;
             reactions to aspirin or other non-steroidal anti-inflammatory drugs(including COX-2&#xD;
             inhibitors).&#xD;
&#xD;
         17. Malignant tumors other than basal cell or squamous cell carcinoma of the skin,&#xD;
             CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and&#xD;
             intraepithelial carcinoma of other areas Within 5 years of consent date.&#xD;
&#xD;
         18. Medical history of hypersensitivity to the components of the investigational products.&#xD;
             (The components of test drug 1 and 2, including the Rhein-based drug)&#xD;
&#xD;
         19. Patients with an allergic reaction to sulfonamide.&#xD;
&#xD;
         20. Patients with galactose intolerance, lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption.&#xD;
&#xD;
         21. Subjects who have not reached the prescribed period after receiving contraindicated&#xD;
             medication or treatment before participation in this clinical trial.&#xD;
&#xD;
         22. Patients receiving contraindicated medication.&#xD;
&#xD;
         23. Alcohol and other drug abuse cases based on 6 months before screening.&#xD;
&#xD;
         24. Pregnant women or nursing mothers who are not willing to stop breastfeeding.&#xD;
&#xD;
         25. Female who do not fall into one or more of the following categories(In other words,&#xD;
             only the following female can participate:)&#xD;
&#xD;
               -  (1) Menopause (non-therapy-induced amenorrhea of more than 12 months) Female&#xD;
&#xD;
               -  (2) Female infertility due to surgery (no ovaries and / or uterus)&#xD;
&#xD;
               -  (3) If you have sexual intercourse with only one male partner who has been&#xD;
                  confirmed to have no semen after fertilization.&#xD;
&#xD;
               -  (4) Female subjects who agreed to abstinence during the clinical trial period.&#xD;
&#xD;
               -  If the subject is assured of an abstinence throughout the trial period.(e.g.&#xD;
                  clergy)&#xD;
&#xD;
               -  However, intermittent abstinence (eg, contraception using ovulation period,&#xD;
                  symptothermal) or coitus interrupts is not a case of consent for abstinence.&#xD;
&#xD;
               -  (5) For women of childbearing age, the following methods or methods of&#xD;
                  contraception use the effective method of contraception to be used during the&#xD;
                  period of this clinical trial:&#xD;
&#xD;
               -  Oral contraceptive&#xD;
&#xD;
               -  The contraceptive patch&#xD;
&#xD;
               -  Intra uterine device (IUD)&#xD;
&#xD;
               -  contraceptive implant&#xD;
&#xD;
               -  contraceptive injection&#xD;
&#xD;
               -  intrauterine hormonal apparatus&#xD;
&#xD;
               -  Tubal ligation and infertility surgery&#xD;
&#xD;
         26. If 30 days have not elapsed after the date of signing of the previous clinical trial&#xD;
             or currently participating in other clinical trials.&#xD;
&#xD;
         27. Patients who are scheduled for surgery during the clinical trial period or who have&#xD;
             difficulties in completing the protocol during this clinical trial due to other&#xD;
             reasons.&#xD;
&#xD;
         28. In addition to the above, other diseases that the investigator judges to be&#xD;
             inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Whan-Seok Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seon-Mee Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-na Jo</last_name>
    <phone>82-70-4335-5448</phone>
    <email>ynjo@symyoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung Woon Yang</last_name>
    <phone>82-31-354-0604</phone>
    <email>yangsw7@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whan-Seok Choi, M.D., Ph.D.</last_name>
      <phone>82-2-2258-6285</phone>
      <email>fmchs@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Whan-Seok Choi, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chul-Min Kim, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Hyeon Ju, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seon-Mee Kim, MD, PhD</last_name>
      <phone>82-2-2626-3276</phone>
      <email>ksmpdh@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seon-Mee Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Li Z, Meng D, Li G, Xu J, Tian K, Li Y. Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. Inflammation. 2015 Aug;38(4):1563-72. doi: 10.1007/s10753-015-0131-3.</citation>
    <PMID>25687638</PMID>
  </reference>
  <reference>
    <citation>Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104. doi: 10.1177/1759720X09359104.</citation>
    <PMID>22870441</PMID>
  </reference>
  <reference>
    <citation>Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015 Mar;38(3):245-52. doi: 10.1007/s40264-015-0266-z. Review.</citation>
    <PMID>25652235</PMID>
  </reference>
  <reference>
    <citation>Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998 Nov;35(5):347-59. Review.</citation>
    <PMID>9839088</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Whan-Seok Choi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Diacerein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Diacetylrhein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

